Physician profile
Michael Stenzel
NPI 1356386858
$1,073.68
in general payments reported to CMS, 2019-2025
11 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $45.97 · 2021: $52.06 · 2022: $187 · 2023: $100 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.97 | 2019-2025 | Creon, Skyrizi, Linzess |
| Shionogi INC | $224.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.53 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $84.97 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $47.76 | 2019-2025 | |
| Braintree Laboratories, INC. | $22.24 | 2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $17.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.88 | 2025 | Voquezna |
| Ucb, INC. | $13.82 | 2019 | |
| Celgene Corporation | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stenzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.